Pfizer has entered into a strategic licensing agreement with China’s YaoPharma to advance next-generation therapies for obesity and metabolic diseases. Through the deal, which is valued up to US$2.085 B, Pfizer gains exclusive global rights to YP05002, a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in early-stage clinical development for chronic weight management. This agreement enables Pfizer to strengthen its obesity portfolio, representing a significant move to diversify the company’s metabolic disease pipeline and regain momentum in a market dominated by leading competitors.